News and Announcements
Aeeris HY Report; Moves to More Efficient and Effective Commercial Process
- Published February 24, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Aeeris Limited (ASX:AER) is pleased to present its financial results for the Half year ended 31st December 2016, and accompanying Appendix 4D. The Company today announced EBITDA of $0.2 million for the six months to 31st December 2016 and a Maiden Net Profit After Tax of $78,477. The Company’s Net Assets at 31st December 2016 were $2.8 million (30th June 2016: $2.7 million).
KEY TAKEAWAYS:
- Total Revenue for H1FY17 of $1,155,767.
- EBITDA (Earnings Before Interest, Tax, Depreciation & Amortisation) of $203,432.
- Net Profit After Tax of $78,477.
- Basic earnings per share of 0.14 cents.
As previously reported, the Company was focused during the Reporting Period on a significant restructure of operations aimed at reducing operating costs and cash burn, and enhancing prices, sales activity and revenues.
This process was completed resulting in improved financial performance, and further financial progress is expected during the Second Half.
Commenting on the results, Aeeris Executive Chairman and CEO, Kerry Plowright said:
“We are pleased with our financial progress having re-set the way we do business, towards are far more efficient and effective commercial process.”
“We are currently laser-focused on immediate sales opportunities and growing revenues by driving new customers to our core products and services – All Alerts™, Situation Room™ and Safe@Work™. We have recently announced a number of new customers for these technologies and services, and we look forward to further announcements in due course”.
The Company continues to consider potential acquisition proposals.
To view the full ASX Results, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
